Vol.61 No.1 January 2013
Risk factors of linezolid-associated thrombocytopenia
Department of Pharmacy, Bell Land General Hospital, 500-3 Higashiyama, Naka-ku, Sakai, Osaka, Japan
Abstract
Thrombocytopenia is known as a major adverse event of linezolid(LZD) therapy. This study investigated the risk factors associated with the development of thrombocytopenia in patients who received LZD therapy. This study retrospectively evaluated 81 patients who had undergone intravenous administration of LZD, in 49 patients of whom (60.5%), thrombocytopenia occurred. The mean duration of LZD therapy was 16.0±12.3 days. The platelet count(PLT) decreased significantly from the start to the end of LZD therapy (P<0.001, 27.2×104±11.5×104 vs. 17.7×104±10.9×104 platelets/μL). The patients with renal insufficiency were not considered to be at risk for development of thrombocytopenia. Logistic regression analysis revealed two independent risk factors for thrombocytopenia: albumin <2.5 g/dL(OR=3.53, 95% CI 1.10-11.4; P<0.05) and duration of LZD therapy)≥14 days (OR=6.33, 95% CI 1.99-20.2; P<0.005). Our results suggest that low Alb levels and the duration of LZD therapy are risk factors for developing LZD-related thrombocytopenia.
Key word
linezolid, thrombocytopenia, risk factor
Received
July 12, 2012
Accepted
November 2, 2012
Jpn. J. Chemother. 61 (1): 1-4, 2013
